iSERA Lifesciences Limited (BOM:534920)
India · Delayed Price · Currency is INR 143.90
0.00 (0.00%)
At close: Aug 21, 2026
iSERA Lifesciences Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 13.55 | 13.55 | - | - | - | - |
Other Revenue | 0.14 | 0.14 | 2.65 | - | - | - |
| 13.69 | 13.69 | 2.65 | - | - | - | |
Revenue Growth | 416.03% | 416.03% | -87.57% | - | - | - |
Cost of Revenue | 4.74 | 4.51 | - | - | - | - |
Gross Profit | 8.95 | 9.18 | 2.65 | - | - | - |
Selling, General & Admin | 0.57 | 0.57 | 1.26 | 0.99 | 1.16 | 1.06 |
Other Operating Expenses | 8.79 | 5.81 | - | - | - | - |
Operating Expenses | 9.36 | 6.38 | 1.26 | 0.99 | 1.16 | 1.06 |
Operating Income | -0.41 | 2.8 | 1.39 | -0.99 | -1.16 | -1.06 |
Interest & Investment Income | 0.57 | 0.57 | - | - | - | - |
Other Non Operating Income (Expenses) | - | - | - | - | -0 | -0 |
EBT Excluding Unusual Items | 0.16 | 3.36 | 1.39 | -0.99 | -1.16 | -1.06 |
Other Unusual Items | - | - | - | 0.05 | 0.05 | - |
Pretax Income | 0.16 | 3.36 | 1.39 | -0.94 | -1.12 | -1.06 |
Income Tax Expense | 0.77 | 0.77 | - | - | - | - |
Net Income | -0.61 | 2.59 | 1.39 | -0.94 | -1.12 | -1.06 |
Net Income to Common | -0.61 | 2.59 | 1.39 | -0.94 | -1.12 | -1.06 |
Net Income Growth | - | 86.62% | - | - | - | - |
Shares Outstanding (Basic) | 2 | 8 | 0 | 0 | 0 | - |
Shares Outstanding (Diluted) | 2 | 8 | 0 | 0 | 0 | - |
Shares Change | - | 2525.54% | 6.76% | 0.09% | 842.55% | - |
EPS (Basic) | -0.29 | 0.31 | 4.34 | -3.14 | -3.73 | - |
EPS (Diluted) | -0.29 | 0.31 | 4.34 | -3.14 | -3.73 | - |
EPS Growth | - | -92.89% | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | -53.54 | -14.02 | -0.61 | -1.23 | -3 |
Free Cash Flow Per Share | - | -6.37 | -43.77 | -2.02 | -4.12 | - |
Gross Margin | 65.38% | 67.07% | 100.00% | - | - | - |
Operating Margin | -3.00% | 20.44% | 52.41% | - | - | - |
Profit Margin | -4.49% | 18.95% | 52.41% | - | - | - |
Free Cash Flow Margin | - | -391.25% | -528.54% | - | - | - |
EBITDA | - | - | - | - | - | -0.07 |
D&A For EBITDA | - | - | - | - | - | 0.99 |
EBIT | -0.41 | 2.8 | 1.39 | -0.99 | -1.16 | -1.06 |
EBIT Margin | -3.00% | 20.44% | 52.41% | - | - | - |
Effective Tax Rate | 493.59% | 22.89% | - | - | - | - |
Revenue as Reported | 14.25 | 14.25 | - | - | - | - |
Advertising Expenses | - | 0.01 | 0.05 | 0.05 | 0.05 | - |